Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published 11 April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Sarcopenic obesity and complex interventions with nutrition and exercise in community-dwelling older persons – a narrative review

Goisser S, Kemmler W, Porzel S, Volkert D, Sieber CC, Bollheimer LC, Freiberger E

Clinical Interventions in Aging 2015, 10:1267-1282

Published Date: 6 August 2015

Lifestyle diseases and cardiovascular risk factors are interrelated to deficiencies of major substrates in ATP synthesis

Jørn Ditzel, Hans-Henrik Lervang

Vascular Health and Risk Management 2010, 6:829-836

Published Date: 17 September 2010

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination

Francesca Cagnoni, Christian Achiri Ngu Njwe, Augusto Zaninelli, et al

Vascular Health and Risk Management 2010, 6:549-559

Published Date: 28 June 2010

Topical nepafenac in the treatment of diabetic macular edema

David Callanan, Patrick Williams

Clinical Ophthalmology 2008, 2:689-692

Published Date: 5 December 2008

Zebrafish: An in vivo model for the study of neurological diseases

J D Best, Wendy K Alderton

Neuropsychiatric Disease and Treatment 2008, 4:567-576

Published Date: 6 June 2008

Almotriptan in the treatment of migraine

Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe Nappi

Neuropsychiatric Disease and Treatment 2007, 3:799-809

Published Date: 15 January 2008

Continuous levodopa for advanced Parkinson’s disease

Christofer Lundqvist

Neuropsychiatric Disease and Treatment 2007, 3:335-348

Published Date: 15 July 2007